Targeting GLUT1 to Control Autoimmunity in Type 1 Diabetes

Type 1 Diabetes is an autoimmune disease in which immune cells contribute to the destruction of insulin-producing pancreatic beta cells. This study investigates whether targeting glucose transporter 1 (GLUT1), a transporter involved in immune cell metabolism, may help modulate autoimmune responses associated with Type 1 Diabetes. The study uses previously collected and biobanked peripheral blood mononuclear cells (PBMCs) from individuals with Type 1 Diabetes. No additional visits, blood draws, or study-specific procedures will be performed on human participants.

NCT Number	NCT07695727
Lead Sponsor	IRCCS San Raffaele
Conditions	Type 1 Diabetes, Autoimmunity
Enrollment	84 participants
Start Date	2026-09
Primary Completion	2029-09 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-14